Short-Term Morphofunctional Changes in Previously Treated Neovascular AMD Eyes Switched to Brolucizumab
Article in Journal of Clinical Medicine (September 2022)
The most recent citing publications are shown below. View all 52 publications that cite this research output on Dimensions.
Switching to brolucizumab from aflibercept in age-related macular degeneration with type 1 macular neovascularization and polypoidal choroidal vasculopathy: an 18-month follow-up study
Article in Graefe's Archive for Clinical and Experimental Ophthalmology (August 2022)
Short-term morpho-functional changes in previously treated neovascular AMD eyes switched to brolucizumab
Preprint in Research Square (May 2022)